Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40H21 | ISIN: GB00BRXB0C07 | Ticker-Symbol:
NASDAQ
05.06.25 | 21:59
29,530 US-Dollar
0,00 % 0,000
1-Jahres-Chart
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Chart 1 Jahr
5-Tage-Chart
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 5-Tage-Chart

Aktuelle News zur KINIKSA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKiniksa sets Phase 2/3 trial for heart drug KPL-3871
DoKiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis38- KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast...
► Artikel lesen
DiKiniksa Pharmaceuticals International, plc - 8-K, Current Report1
KINIKSA PHARMACEUTICALS Aktie jetzt für 0€ handeln
30.04.Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces GRAMMY Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis1
29.04.Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report-
29.04.Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance3
29.04.Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.11 beats by $0.09, revenue of $137.7M beats by $5.99M1
29.04.Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution300- ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387...
► Artikel lesen
28.04.Examining the Future: Kiniksa Pharmaceuticals' Earnings Outlook1
24.04.Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 20251
23.04.Kiniksa Pharmaceuticals International, plc - 8-K, Current Report1
06.03.Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst5
25.02.Kiniksa Pharmaceuticals International, plc - S-8, Securities to be offered to employees in employee benefit plans-
25.02.Kiniksa Pharmaceuticals International, plc - 10-K, Annual Report-
25.02.Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset5
25.02.Kiniksa to launch Phase 2/3 trial for heart drug KPL-3872
25.02.Kiniksa Pharmaceuticals, Ltd. Q4 Earnings Summary-
25.02.Kiniksa startet Phase-2/3-Studie für Herzmedikament KPL-387-
25.02.Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy327- Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 - - KPL-387 Phase 1 single ascending dose data support potential monthly dosing - - Kiniksa...
► Artikel lesen
25.02.Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution306- ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively -- ARCALYST 2025 net product revenue expected to be $560 - $580 million --...
► Artikel lesen
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1